Gut microbiome and cancer immunotherapy
Gut microbiome and cancer immunotherapy
复制标题
DOI：
10.1016/j.canlet.2019.01.015
复制
发表时间：
2019-01-01
期刊：
影响因子：
9.7
通讯作者：
Zhang, Peng
中科院分区：
文献类型：
--
作者：
Li, Weina;Deng, Yu;Zhang, Peng
微生物组变得至关重要，因为人类健康和疾病之间的平衡可以由肠道微生物组介导。肠道微生物组可以局部和全身调节宿主免疫系统。癌症免疫治疗已经成为治疗癌症患者的一种有前途的方法。越来越多的证据支持微生物组影响癌症免疫疗法的治疗效果，特别是免疫检查点抑制剂。在这里，我们讨论了肠道微生物组，癌症，免疫和癌症免疫治疗之间的相互关系，重点是免疫治疗。此外，我们简要介绍了影响治疗效果的相关挑战，并提出了可能的解决方案。
Microbiome is becoming crucial in that the balance between human health and disease can be mediated by the gut microbiome. The gut microbiome can modulate the host immune system both locally and systemically. Cancer immunotherapy has emerged as a promising way in the treatment of patients with cancer. Accumulating evidence supports that microbiome affects the therapeutic efficacy of cancer immunotherapy, particularly immune checkpoint inhibitors. Here, we discuss the mutual relationship among gut microbiome, cancer, immunity, and cancer immunotherapy, with a focus on immunotherapy. Also, we briefly introduce the relevant challenges that affect the therapeutic efficacy and present the possible solutions.